Nalan Akyurek

Prof. Dr. Nalan Akyurek

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2011 in Cancer
Verified
Journal Article
Open access
PDF file
NANalan Akyurek
Nalan Akyurek
AUAysegul Uner
Aysegul Uner
MBMustafa Benekli
Mustafa Benekli
IBIbrahim Barista
Ibrahim Barista
BACKGROUND: Diffuse large B‐cell lymphomas (DLBCLs) are a biologically heterogeneous group in which various gene alterations have been reported. The aim of this study was to investigate the frequency and prognostic impact of BCL2, BCL6, and MYC rearrangements in cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R‐CHOP)‐treated DLBCL cases.METHODS: Tissue microarrays were constructed from 239 cases of DLBCL, and the expressions of CD10, BCL6, MUM1/IRF4, and BCL2 were evaluated by immunohistochemistry. MYC, BCL2, and BCL6 rearrangements were investigated by interphase fluorescence in situ hybridization on tissue microarrays. Survival analysis was constructed from 145 R‐CHOP–treated patients.RESULTS: MYC, BCL2, and BCL6 rearrangements were detected in 14 (6%), 36 (15%), and 69 (29%) of 239 DLBCL patients. Double or triple rearrangements were detected in 7 (3%) of 239 DLBCL cases. Of these, 4 had BCL2 and MYC, 2 had BCL6 and MYC, and 1 had BCL2, BCL6, and MYC rearrangements. The prognosis of these cases was extremely poor, with a median survival of 9 months. MYC rearrangement was associated with significantly worse overall survival (P = .01), especially for the cases with GC phenotype (P = .009). BCL6 rearrangement also predicted significantly shorter overall survival (P = .04), especially for the non‐GC phenotype (P = .03). BCL2 rearrangement had no prognostic impact on outcome. International Prognostic Index (P = .004) and MYC rearrangement (P = .009) were independent poor prognostic factors.CONCLUSIONS: Analysis of MYC gene rearrangement along with BCL2 and BCL6 is critical in identifying high‐risk patients with poor prognosis. Cancer 2012. © 2011 American Cancer Society.

18 October 2018 in Turkish Thoracic Journal
Verified
Journal Article
Closed access
ABAyse Baha
Ayse Baha
FYFatma Yildirim
Fatma Yildirim
NKNurdan Kokturk
Nurdan Kokturk
ZGZuleyha Galata
Zuleyha Galata
NANalan Akyurek
Nalan Akyurek
HTHaluk Türktaş3
Haluk Türktaş3
Turkthoracj, Turkish Thoracic Journal

30 June 2006 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
NANalan Akyurek
Nalan Akyurek
LMLeyla Memiş
Leyla Memiş
ÖEÖzgür Ekinci
Özgür Ekinci
NKNurdan Köktürk
Nurdan Köktürk
CÖCan Öztürk
Can Öztürk

2 April 2005 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
ÖUÖmer Uluoğlu
Ömer Uluoğlu
NANalan Akyurek
Nalan Akyurek
AÜAytuğ Üner
Aytuğ Üner
UCUğur Coşkun
Uğur Coşkun
AÖAyşegul Özdemir
Ayşegul Özdemir
NGNahide Gökçora
Nahide Gökçora

1 July 2017 in Pathology - Research and Practice
Verified
Journal Article
Closed access
BSBurcu Saka
Burcu Saka
ÖEÖzgür Ekinci
Özgür Ekinci
ADAyse Dursun
Ayse Dursun
NANalan Akyurek
Nalan Akyurek

1 January 2023 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
GTGozde Tahtaci
Gozde Tahtaci
NGNazan Günel
Nazan Günel
ASAysu Sadi̇oĞlu
Aysu Sadi̇oĞlu
NANalan Akyurek
Nalan Akyurek
OBOğulcan Boz
Oğulcan Boz
AÜAytuğ Üner
Aytuğ Üner
Background/aim: This study aimed to evaluate the expression of lymphocyte activation gene-3 (LAG-3) and its relationship with programmed cell death ligand-1 (PD-L1) in triple-negative breast cancer (TNBC). Materials and methods: LAG-3 and PD-L1 was evaluated in tumor-infiltrating lymphocytes (TILs) using immunohistochemistry (IHC). The chi-square test was used to estimate the associations between LAG-3, PD-L1 and clinicopathological characteristics. Correlation between LAG-3 stromal TIL (sTIL), LAG-3 intraepitelial TIL (iTIL) and PD-L1 was assessed with using the Spearman's correlation coefficient. Survival analysis was performed using the Kaplan-Meier method. Results: The percentages of LAG-3 sTIL+, LAG-3 iTIL+, PD-L1+ tumor cells and PD-L1+ inflammatory cells were 52%, 42%, 14% and 70%, respectively. A strong positive correlation between LAG-3 sTIL and LAG-3 iTIL (r = 0.874, p < 0.001) and a moderate positive correlation between LAG-3 sTIL and PD-L1 (r = 0.584, p < 0.001) were found. LAG-3 and PD-L1 status did not significantly affect overall survival (OS) (HR: 0.56 (95% CI: 0.15-2.11) (p = 0.397), HR: 2.70 (95% CI: 0.56-13.02) (p = 0.215), respectively). Conclusion: High levels of LAG-3 and PD-L1 expression were detected in patients with TNBC. Although their contribution to survival could not be determined, the high expression rates of PD-L1 and LAG-3 may help identify the subgroup of TNBC that would benefit from immunotherapy.